Get the Stockscreener App
4.10
0.24%
-0.01
Pre-market:
4.24
0.14
+3.41%
Cingulate Inc stock is traded at $4.10, with a volume of 97,893.
It is down -0.24% in the last 24 hours and up +12.02% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.11
Open:
$4.15
24h Volume:
97,893
Relative Volume:
0.68
Market Cap:
$19.66M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1258
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
-7.87%
1M Performance:
+12.02%
6M Performance:
-14.94%
1Y Performance:
-39.42%
1-Day Range:
$4.00
$4.26
1-Week Range:
$3.90
$4.545
52-Week Range:
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.10 | 19.66M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) - TradingView
Breakthrough Once-Daily ADHD Drug Targets $22B Market: Analyst Coverage Reveals Commercial Launch Plans - Stock Titan
Cingulate Inc. (NASDAQ:CING) Sees Large Increase in Short Interest - Defense World
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - mx.advfn.com
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - mx.advfn.com
Cingulate Inc. expands equity plan following stockholder approval - Investing.com
Cingulate Inc Approves Key Proposals at Annual Meeting - TipRanks
Cingulate (NASDAQ:CING) Price Target Raised to $61.00 at Ascendiant Capital Markets - Defense World
Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer - Quantisnow
CING: Ascendiant Capital Raises Price Target to $61.00 | CING St - GuruFocus
Healthcare Tech Leader Life365 Taps Former Nasdaq CEO Jay Roberts to Drive AI-Powered Growth Strategy - Stock Titan
What is Roth Capital’s Estimate for Cingulate Q2 Earnings? - Defense World
McCann Joburg acquires a healthcare marketing company - Bizcommunity
Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD - Nasdaq
Cingulate announces efficacy results from Phase 3 study of CTx-1301 - TipRanks
Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment | CING Stock News - GuruFocus
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire
CING: Roth Capital Lowers Price Target, Maintains Buy Rating | CING Stock News - GuruFocus
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developm - GuruFocus
Cingulate price target lowered to $11 from $12 at Roth Capital - TipRanks
CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developments | CING Stock News - GuruFocus
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN
CING: First Quarter 2025 Results - Yahoo Finance
Cingulate receives FDA meeting feedback on ADHD drug By Investing.com - Investing.com Canada
Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug By Stocktwits - Investing.com India
Cingulate, Inc. Reports Increased Losses Amid R&D Expansion - TipRanks
Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301 - TipRanks
Cingulate (CING) Prepares for NDA Submission for ADHD Treatment - GuruFocus
Cingulate receives FDA meeting feedback on ADHD drug - Investing.com
Cingulate Inc Terminates Grant Agreement with Foundation - TipRanks
Cingulate Inc. Reports First Quarter 2025 Financial Results - GlobeNewswire
27,323 Shares in Cingulate Inc. (NASDAQ:CING) Acquired by Geode Capital Management LLC - Defense World
Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301 - TipRanks
CING Reports Positive Results for CTx-1301 in Food Effect Study - GuruFocus
Cingulate announces results from high-dose fed/fast study of CTx-1301 - TipRanks
Cingulate Announces Positive Top-Line Results from - GlobeNewswire
Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd - marketscreener.com
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD - The Manila Times
Cingulate (NASDAQ:CING) Given New $60.00 Price Target at Ascendiant Capital Markets - Defense World
Analysts’ Top Healthcare Picks: Healthequity (HQY), Cingulate Inc (CING) - The Globe and Mail
Cingulate secures $3m to advance once-daily anxiety treatment - Yahoo Finance
Cingulate wins $3M from private foundation to help develop third time-release drug - The Business Journals
CING: 2024 Financial and Operational Results - Yahoo Finance
Cingulate Inc. (NASDAQ:CING) Shares Purchased by Commonwealth Equity Services LLC - Defense World
Cingulate Inc Secures $3M Grant for Anxiety Drug - TipRanks
Cingulate Receives $3 Million Grant from Private Foundation - GlobeNewswire
Revolutionary Once-Daily Anxiety Drug Gets $3M Boost: Targeting $5.5B Market - Stock Titan
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):